Mobilizing the European Union to accelerate action on bleeding and clotting conditions, promote patient safety, elevate clinical standards and deliver improved health outcomes.
The ETHA is a growing alliance of 26 societies and organizations in the field of thrombosis and hemostasis dedicated to improving awareness, prevention and treatment in Europe.
The mission of the European Thrombosis and Haemostasis Alliance (ETHA) is to give the thrombosis and hemostasis community a voice and to drive prioritisation of thrombosis and hemostasis in the EU patient safety and research programs. With a united focus on raising awareness of bleeding and clotting disorders, ETHA stands together to work with the public as well as decision makers' to provide input into EU health and patient safety strategies.
ETHA is led by Mettine Bos, an Assistant Professor at the Leiden University Medical Center in The Netherlands.
ETHA CONSENSUS STATEMENT
To learn more about ETHA’s initial areas of priority, read its consensus statement, here.
WHAT WE DO
Our aim is to enhance the health outcomes of patients worldwide by promoting funding opportunities for research in thrombosis and hemostasis, while also leveraging education and awareness. To achieve this, we are building relationships with governments, inter-governmental agencies, and regulatory bodies to highlight the importance of thrombosis and hemostasis in promoting better health outcomes. We are also collaborating with the global thrombosis and hemostasis community, as well as other medical specialties with similar interests, to advance common agendas.
Our efforts involve educating policy makers about the burden of disease caused by thrombosis and the effective health interventions available. We also highlight pressing scientific challenges related to thrombosis and hemostasis that require continued funding. Our goal is to position the ETHA as an important voice and EU stakeholder in the field of non-communicable diseases.
Our advocacy efforts aim to prioritize VTE prevention and give the thrombosis and hemostasis community in the EU a unified voice. We provide input to EU health and patient safety strategies, recommend EU research program funding, and encourage the sharing and adoption of best practices.
We prioritize and proactively address public policy issues related to thrombosis and hemostasis and support MEPs and their staff - as well as the media - with resources, including research updates, and distribute basic information, papers, and informational resources to public affairs audiences.
Community building is crucial in the EU to raise awareness about important health issues, such as thrombosis and hemostasis, and to promote the adoption of policies that improve patient outcomes. By engaging with policymakers and other relevant stakeholders, we can build a stronger and more supportive community.